Michelle Riley, DO
Internal Medicine · Avon, OHNPI 1952370090
Payments from drug & device makers
Across 327 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$689
- Lilly USA, LLC$599
- AbbVie$596
- Pfizer$416
- AstraZeneca$407
- Exact Sciences$289
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,582100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $689 |
| Lilly USA, LLC | 40 | $599 |
| AbbVie | 32 | $596 |
| Pfizer | 31 | $416 |
| AstraZeneca | 21 | $407 |
| Exact Sciences | 13 | $289 |
| Boehringer Ingelheim | 16 | $274 |
| Merck | 13 | $236 |
| GSK | 11 | $200 |
| Axsome Therapeutics, Inc. | 6 | $180 |
| Novartis | 9 | $167 |
| Astellas Pharma US Inc | 9 | $164 |
| Johnson & Johnson | 7 | $136 |
| Sanofi Pasteur Inc. | 8 | $129 |
| Amgen | 7 | $112 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| E.r. Squibb & Sons, L.L.C. | 5 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Dynavax Technologies Corporation | 4 | $67 |
| Xeris Pharmaceuticals, Inc. | 3 | $67 |
| Optinose US, Inc. | 3 | $61 |
| Organon | 2 | $52 |
| Dexcom, Inc. | 2 | $50 |
| Corcept Therapeutics | 2 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Vivus LLC | 2 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Bayer | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Bausch Health US, LLC | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
How this compares
$5,582 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $151,125 |
| MounjaroTirzepatide | 85 | $98,400 |
| EliquisApixaban | 90 | $94,773 |
| JardianceEmpagliflozin | 99 | $81,332 |
| JanuviaSitagliptin Phosphate | 60 | $52,814 |
| TrulicityDulaglutide | 49 | $48,808 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $36,895 |
| TradjentaLinagliptin | 48 | $35,413 |
| RybelsusSemaglutide | 27 | $24,237 |
| Nurtec OdtRimegepant Sulfate | 11 | $18,351 |
| XareltoRivaroxaban | 13 | $14,993 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $12,142 |
| InvokanaCanagliflozin | 13 | $8,063 |
| LinzessLinaclotide | 14 | $7,115 |
| MyrbetriqMirabegron | 14 | $6,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $689 | $175,362156 claims |
| Lilly USA, LLCMounjaro, Trulicity | $599 | $147,208134 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $274 | $128,888158 claims |
| PfizerEliquis, Nurtec Odt | $416 | $113,123101 claims |
| MerckJanuvia | $236 | $52,81460 claims |
| GSKTrelegy Ellipta | $200 | $36,89548 claims |
| Johnson & JohnsonXarelto, Invokana | $136 | $23,05626 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $596 | $10,306118 claims |
| Astellas Pharma US IncMyrbetriq | $164 | $6,92914 claims |
| AstraZenecaSymbicort | $407 | $5,55721 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $4,218470 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Avon
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.